Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Anixa Biosciences, Inc.NASDAQ: ANIX
Net Income · Q2 FY2026 · quarter ended Apr 2026
Net income declines year over year
Q2 FY2026 net income of $2.54M (cash outflow) fell 9.8% year over year, ahead of the -17.6% change in trailing-twelve-month net income. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$10.17M (-7.8%) for the fiscal year ending Oct 2026, a step up from the -13.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -$2.54M-1.9% QoQ
- Last fiscal yearOct 2025
- -$11.03M-13.2% YoY
- LTMApr 2026
- -$10.1M-17.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -9.8% | +20.5% | +30.4 pp |
| 1 year | -13.2% | -7.8% | +5.4 pp |
| 3-year CAGR | -7.1% | -1.0% | +6.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.03M) USD
- Year-over-year change
- +13.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (11.03M) | +13.2% |
| FY2024 | 2024-10-31 | (12.7M) | -27.9% |
| FY2023 | 2023-10-31 | (9.93M) | +27.9% |
| FY2022 | 2022-10-31 | (13.77M) | -4.9% |
| FY2021 | 2021-10-31 | (13.13M) | — |
Net Income vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 net income of $10.1M is the smallest of the 10 companies compared; the peer median is $30.92M.
- Its year-over-year change of -17.6% is the 8th highest of 9, against a peer median of +10.0%.
- Over three fiscal years its annual growth of -7.1% compares with a peer median of +0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.28M | -2.6% | +41.5% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $106.93M | +82.4% | — | 892.4% |
| LTM Mar 2026 | $84.93M | -12.0% | -32.8% | — | |
| LTM Mar 2026 | $70.49M | -17.9% | -7.5% | 468.7% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $30.92M | — | +47.5% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $21.54M | -14.9% | +3.3% | — |
| LTM Mar 2026 | $15.24M | +121.8% | — | 27.8% | |
| LTM Mar 2026 | $12.38M | +22.7% | -4.3% | — | |
| LTM Apr 2026 | $10.1M | -17.6% | -7.1% | — | |
| Peer median (excluding ANIX) | $30.92M | +10.0% | +0.2% | 259.6% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Depreciation & Amortization | 60K | 42K | 46K | 37K | (107K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.5M | 6M | 4.42M | 4.42M | 3.68M |
| Change in Working Capital | 78K | 485K | (1.06M) | 526K | 152K |
| Accounts Receivables | 0 | (29K) | (224K) | 97K | 173K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (96K) | 129K | (59K) | 319K | (360K) |
| Other Working Capital | 174K | 385K | (777K) | 110K | 339K |
| Other Non-Cash Items | 549K | 752K | 313K | 380K | 129K |
| Operating Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 7K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (16.5M) | (22.49M) | (44.41M) | (63.77M) | (44.36M) |
| Sales of Investments | 12.54M | 11.76M | 38.81M | 68.05M | 49.23M |
| Other Investing Activities | 35K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.92M) | (10.73M) | (5.6M) | 4.28M | 4.87M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 31.13M | 0 | 0 | 2.96M | 2.28M |
| Common Stock Repurchased | 0 | 0 | 0 | (6K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 440K | 452K | 366K | 466K | 0 |
| Financing Cash Flow | 31.57M | 452K | 366K | 3.42M | 2.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 22.71M | (16.77M) | (11.45M) | 356K | (27K) |
| Free Cash Flow | (4.94M) | (6.49M) | (6.21M) | (7.34M) | (7.17M) |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.